Lunai Bioworks Announces 1-for-8 Reverse Stock Split to Regain Nasdaq Compliance
LNAI sits 68% above its 52-week low of $0.151.
Summary
Lunai Bioworks will execute a 1-for-8 reverse stock split on May 22, 2026, a move aimed at boosting its share price to meet Nasdaq's minimum bid requirement and avoid delisting.
Key Events · Corporate Governance and Compliance · LNAI
-
Reverse Stock Split Finalized
Lunai Bioworks announced a 1-for-8 reverse stock split, effective May 22, 2026. This follows shareholder approval on May 8, 2026, for a split ratio between 1-for-3 and 1-for-30.
-
Nasdaq Compliance Effort
The primary purpose of the split is to increase the stock price above $1.00 to regain compliance with Nasdaq Listing Rule 5550(a)(2) and avoid delisting.
-
Previous Reverse Split History
This marks the second reverse stock split for the company, following a 1-for-10 split on September 30, 2025, highlighting ongoing challenges with its share price.
Analysis · LNAI · Life Sciences
This 8-K announces the final 1-for-8 reverse stock split ratio and its effective date of May 22, 2026. While shareholders previously approved a reverse split, this filing provides the definitive terms. The split is a critical step for Lunai Bioworks to increase its per-share price and meet Nasdaq's minimum bid price requirement, following multiple delisting notices and a prior reverse split in 2025. Failure to comply would result in delisting, making this a necessary but negative action reflecting ongoing challenges.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LNAI was trading at $0.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.1M. The 52-week trading range was $0.15 to $4.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.